Cargando…

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy

Since 2005, the approved first-line treatment of metastatic renal cell carcinoma consists in tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptors (VEGFRs). Axitinib is an oral second-generation TKI and a potent VEGFR inhibitor with a half maximal inhibitory co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellesoeur, Audrey, Carton, Edith, Alexandre, Jerome, Goldwasser, Francois, Huillard, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614734/ https://www.ncbi.nlm.nih.gov/pubmed/29033542 http://dx.doi.org/10.2147/DDDT.S109640

Ejemplares similares

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
por: Tiako Meyo, Manuela, et al.
Publicado: (2022)

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib
por: Noé, Gaёlle, et al.
Publicado: (2016)

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone but decide wisely
por: Huillard, Olivier, et al.
Publicado: (2020)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
por: Narayan, Vivek, et al.
Publicado: (2016)

Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report
por: Koie, Takuya, et al.
Publicado: (2013)

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Venur, Vyshak Alva, et al.
Publicado: (2017)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
por: Chittoria, Namita, et al.
Publicado: (2016)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Axitinib in metastatic renal cell carcinoma: single center experience
por: Buraczewska, Agnieszka, et al.
Publicado: (2017)

Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
por: Gross-Goupil, Marine, et al.
Publicado: (2013)

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
por: Murphy, Danielle A, et al.
Publicado: (2020)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma
por: Godo, Shigeo, et al.
Publicado: (2018)

Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
por: Kimura, Masashi, et al.
Publicado: (2019)

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England
por: Meng, Jie, et al.
Publicado: (2018)

Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation
por: Vlachostergios, Panagiotis J.
Publicado: (2020)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma
por: Saade, Anastasia, et al.
Publicado: (2018)

First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
por: Numakura, Kazuyuki, et al.
Publicado: (2020)

First referral to an integrated onco-palliative care program: a retrospective analysis of its timing
por: Barth, Claire, et al.
Publicado: (2020)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
por: Kimura, Shoichi, et al.
Publicado: (2023)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
por: Murata, Masaki, et al.
Publicado: (2019)

GZ17-6.02 and axitinib interact to kill renal carcinoma cells
por: Booth, Laurence, et al.
Publicado: (2022)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
por: Wei, Na, et al.
Publicado: (2018)

Combination therapy of transcatheter arterial chemoembolization with axitinib for the treatment of inoperable hepatocellular carcinoma
por: Nouso, Kazuhiro, et al.
Publicado: (2020)

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
por: Johnson, Alison C., et al.
Publicado: (2017)

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Noé, Gaëlle, et al.
Publicado: (2019)

Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma
por: Doherty, Gary Joseph, et al.
Publicado: (2018)

Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gf6dplkcbnj7298t260n8rh5kt